1.
Anaerobe
; 84: 102788, 2023 Dec.
Article
in English
| MEDLINE
| ID: mdl-37931679
ABSTRACT
Among 23 patients with multiply recurrent Clostridioides difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.